ANI Pharmaceuticals (NASDAQ:ANIP) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $80.00 price objective on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $62.49 on Friday. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The firm’s fifty day simple moving average is $58.40 and its 200-day simple moving average is $58.06. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,700 shares of company stock valued at $610,201. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE boosted its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV boosted its holdings in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after acquiring an additional 579 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, HighTower Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $222,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.